Comparative Pharmacology
Head-to-head clinical analysis: LARIN 1 5 30 versus LARIN 24 FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN 1 5 30 versus LARIN 24 FE.
LARIN 1.5/30 vs LARIN 24 FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial structure, reducing implantation likelihood.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet (20 mcg ethinyl estradiol / 1 mg norethindrone acetate) orally once daily for 24 days, followed by 1 iron-containing placebo tablet (75 mg ferrous fumarate) orally once daily for 4 days.
None Documented
None Documented
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Ethinyl estradiol: ~13 hours (range 7–20); norethindrone: ~8 hours (range 5–14). Half-life supports once-daily dosing; steady state achieved within 5–7 days.
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Ethinyl estradiol: 40% renal, 60% fecal; norethindrone: 40% renal, 60% fecal.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive